A study to measure the frequencies of type 3 pro-inflammatory and anti-inflammatory cell subsets in Axial Spondyloarthritis AxSpA patients following secukinumab treatment and to discriminate these profiles between responders and non-responders
Latest Information Update: 02 Jan 2024
At a glance
- Drugs Secukinumab (Primary)
- Indications Axial spondyloarthritis
- Focus Therapeutic Use
Most Recent Events
- 02 Jan 2024 New trial record